Mirum Pharmaceuticals Inc (MIRM)

NASDAQ
Currency in USD
49.63
+0.61(+1.24%)
Closed·
After Hours
49.99+0.36(+0.73%)
·
MIRM Scorecard
Full Analysis
4 analysts have revised their earnings downwards for the upcoming period
MIRM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
48.1949.91
52 wk Range
27.1054.23
Key Statistics
Edit
Prev. Close
49.02
Open
48.19
Day's Range
48.19-49.91
52 wk Range
27.1-54.23
Volume
442.13K
Average Vol. (3m)
428.51K
1-Year Change
91.47%
Book Value / Share
4.76
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MIRM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
68.60
Upside
+38.22%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Mirum Pharmaceuticals Inc News & Analysis

Show more

Mirum Pharmaceuticals Inc Company Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Employees
334

Mirum Pharmaceuticals Inc SWOT Analysis


Strategic Expansion
Learn about Mirum's international market expansion, pipeline developments, and upcoming clinical trial readouts that could drive future growth and profitability
Analyst Optimism
Delve into analyst perspectives, with price targets ranging from $73 to $76, reflecting confidence in Mirum's growth potential and market positioning
Financial Momentum
Explore Mirum's robust financial performance, including 88% year-over-year revenue increase and raised 2025 guidance, despite current net losses
Rare Disease Pionee
Mirum Pharmaceuticals leads in rare liver disease therapies, with impressive revenue growth and a diverse product portfolio addressing unmet medical needs
Read full SWOT analysis

Mirum Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue of $111.6M beat forecasts by $13.58M; EPS of -0.3 slightly better than expected
  • Full-year revenue guidance raised to $435-$450M; stock rose 3.32% in aftermarket trading to $42.59
  • 61% YoY revenue growth driven by strong product demand and international expansion
  • R&D expenses at $46M including $7M in milestone payments; cash and investments at $298.6M
  • Enrollment for VISTA study expected to complete by Q3 2025; focus on expanding rare disease pipeline
Last Updated: 05/07/2025, 05:14 PM
Read Full Transcript

Compare MIRM to Peers and Sector

Metrics to compare
MIRM
Peers
Sector
Relationship
P/E Ratio
−31.8x−6.9x−0.4x
PEG Ratio
−0.57−0.140.00
Price / Book
10.5x−0.6x2.6x
Price / LTM Sales
6.5x5.1x3.1x
Upside (Analyst Target)
46.1%157.7%51.1%
Fair Value Upside
Unlock31.2%8.9%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 68.60
(+38.22% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.30 / -0.31
Revenue / Forecast
111.60M / 98.02M
EPS Revisions
Last 90 days

MIRM Income Statement

People Also Watch

165.34
NTRA
+0.60%
55.48
HIMS
-2.92%
74.66
ANF
-5.19%
161.41
CAH
+0.55%
99.74
BSX
+1.20%

FAQ

What Is the Mirum Pharmaceuticals (MIRM) Stock Price Today?

The Mirum Pharmaceuticals stock price today is 49.63

What Stock Exchange Does Mirum Pharmaceuticals Trade On?

Mirum Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Mirum Pharmaceuticals?

The stock symbol for Mirum Pharmaceuticals is "MIRM."

What Is the Mirum Pharmaceuticals Market Cap?

As of today, Mirum Pharmaceuticals market cap is 2.46B.

What Is Mirum Pharmaceuticals's Earnings Per Share (TTM)?

The Mirum Pharmaceuticals EPS (TTM) is -1.61.

When Is the Next Mirum Pharmaceuticals Earnings Date?

Mirum Pharmaceuticals will release its next earnings report on Jul 31, 2025.

From a Technical Analysis Perspective, Is MIRM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Mirum Pharmaceuticals Stock Split?

Mirum Pharmaceuticals has split 0 times.

How Many Employees Does Mirum Pharmaceuticals Have?

Mirum Pharmaceuticals has 334 employees.

What is the current trading status of Mirum Pharmaceuticals (MIRM)?

As of Jun 15, 2025, Mirum Pharmaceuticals (MIRM) is trading at a price of 49.63, with a previous close of 49.02. The stock has fluctuated within a day range of 48.19 to 49.91, while its 52-week range spans from 27.10 to 54.23.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.